• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM
Click for more information
6.56% 28.5¢

IMMUTEP LIMITED - Announcements

Market Cap $486.6M  ! watchlist Created with Sketch. Add to my watchlist

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMMInvestor Presentation October 201218/10/12
IMMAnnual Report to shareholders17/10/12
IMMNotice of Annual General Meeting/Proxy Form15/10/12
IMMPoster Interim Results CAN-00315/10/12
IMMPOSITIVE INTERIM DATA FROM CAN-003 TRIAL OF CVACPRICE SENSITIVE15/10/12
IMMQuarterly newsletter update on CANVAS study progress04/10/12
IMMPrima Newsletter04/10/12
IMMAnnual Report on Form 20-F filed with SEC04/10/12
IMMPRIMA BIOMED TO PRESENT AT CANCER IMMUNOTHERAPY CONFERENCE03/10/12
IMMPrima to present at BIOX21/09/12
IMMRemuneration package for incoming CEO31/08/12
IMMAppendix 4E & 2012 Full Year Statutory AccountsPRICE SENSITIVE31/08/12
IMMAppendix 3B14/08/12
IMMPrima to release interim Cvac clinical dataPRICE SENSITIVE30/07/12
IMMAppendix 4C - quarterlyPRICE SENSITIVE27/07/12
IMMShareholder Briefing presentation15/06/12
IMMShareholder Briefing - Webcast and dial in details13/06/12
IMMPrima Newsletter08/06/12
IMMCripto-1 program updatePRICE SENSITIVE08/06/12
IMMDubai UpdatePRICE SENSITIVE08/06/12
IMMPRR to list on the Frankfurt Stock Exchange05/06/12
IMMShareholder briefing31/05/12
IMMInitial Director's Interest Notice24/05/12
IMMFinal Director's Interest Notice24/05/12
IMMChanges to the Board and senior managementPRICE SENSITIVE24/05/12
IMMDeutsche Health Care Conference04/05/12
IMMChange of Director's Interest Notice01/05/12
IMMAppendix 4C - quarterlyPRICE SENSITIVE27/04/12
IMMInvestor Presentation April 201216/04/12
IMMRegistration Statement on Form 20-F filed with SEC13/04/12
IMMPrima BioMed to list on NASDAQ on April 1613/04/12
IMMCanadian Patent Granted to CVPRICE SENSITIVE11/04/12
IMMAppendix 3B27/03/12
IMMInvestor Presentation March 201219/03/12
IMMAppendix 3B15/03/12
IMMTGA Manufacturing License granted for CVac in AustraliaPRICE SENSITIVE15/03/12
IMMAppendix 3B13/03/12
IMMHalf Yearly Report and AccountsPRICE SENSITIVE28/02/12
IMMAppendix 3B27/02/12
IMMResponse to ASX Price Query LetterPRICE SENSITIVE27/02/12
IMMANZGOG Cancer Vaccine Presentation24/02/12
IMMPrima Newsletter17/02/12
IMMFiles registration statement for listing of ADR's on NASDAQ14/02/12
IMMPatient enrollment commences for CVac CANVAS TrialPRICE SENSITIVE03/02/12
IMMJAPANESE PATENT GRANTED FOR CRIPTO-1 ANTIBODYPRICE SENSITIVE17/01/12
IMMAppendix 4C - quarterlyPRICE SENSITIVE17/01/12
IMMAppendix 3B09/01/12
IMMProgram update on Cripto-1 anti-cancer mABPRICE SENSITIVE30/12/11
IMMProgram update on oral cervical cancer vaccinePRICE SENSITIVE28/12/11
IMMAppendix 3B23/12/11
IMMAppendix 3B16/12/11
IMMAppendix 3B09/12/11
IMMAppendix 3B02/12/11
IMMDeutsche Bank Presentation December 201102/12/11
IMMNotification of expiry of Options25/11/11
IMMAppendix 3B22/11/11
IMMAppendix 3B15/11/11
IMMResults of Meeting03/11/11
IMMChairman's Address to Shareholders03/11/11
IMMAppendix 3B02/11/11
IMMTeleconference details for Annual General Meeting02/11/11
IMMPrima Newsletter31/10/11
IMMPrima Newsletter31/10/11
IMMCVac granted manufacturing authorisation in GermanyPRICE SENSITIVE25/10/11
IMMAppendix 3B24/10/11
IMMPartnership with The City Hospital DubaiPRICE SENSITIVE24/10/11
IMMAppendix 4C - quarterlyPRICE SENSITIVE21/10/11
IMMAppendix 3B11/10/11
IMMAppendix 3B30/09/11
IMMAnnual Report to shareholders30/09/11
IMMNotice of Annual General Meeting/Proxy Form30/09/11
IMMAppendix 3B21/09/11
IMMPrima BioMed Presentation September 201114/09/11
IMMCVac Phase III CANVAS Ovarian Cancer Clinical UpdatePRICE SENSITIVE14/09/11
IMMAppendix 3B13/09/11
IMMPrima completes patient enrolement for CVac Phase IIbPRICE SENSITIVE12/09/11
ACR +SandP Indices Announces September Quarterly RebalancePRICE SENSITIVE09/09/11
IMMAppendix 3B05/09/11
IMMPrima BioMed included in SP-ASX 30002/09/11
IMMAppendix 3B31/08/11
IMMDiversity Policy31/08/11
IMMPreliminary Final ReportPRICE SENSITIVE31/08/11
IMMAmended Appendix 3B22/08/11
IMMAppendix 3B22/08/11
IMMChange of Director's Interest Notice08/08/11
IMMChange of Director's Interest Notice08/08/11
IMMChange of Director's Interest Notice08/08/11
IMMChange of Director's Interest Notice08/08/11
IMMChange of Director's Interest Notice08/08/11
IMMAppendix 3B08/08/11
IMMEURO 4.1 MILLION GRANT TO SUPPORT CVACPRICE SENSITIVE05/08/11
IMMResponse to ASX Price QueryPRICE SENSITIVE05/08/11
IMMAppendix 4C - quarterlyPRICE SENSITIVE29/07/11
IMMAppendix 3B28/07/11
PGL +Progen Subsidiary Secures New Manufacturing ContractsPRICE SENSITIVE20/07/11
IMMAppendix 3B19/07/11
IMMChange of Director's Interest Notice19/07/11
IMMChange of Director's Interest Notice19/07/11
IMMAppendix 3B15/07/11
IMMAppendix 3B14/07/11
IMMInvestor Presentation October 2012
18/10/12
IMMAnnual Report to shareholders
17/10/12
IMMNotice of Annual General Meeting/Proxy Form
15/10/12
IMMPoster Interim Results CAN-003
15/10/12
IMMPOSITIVE INTERIM DATA FROM CAN-003 TRIAL OF CVAC
15/10/12PRICE SENSITIVE
IMMQuarterly newsletter update on CANVAS study progress
04/10/12
IMMPrima Newsletter
04/10/12
IMMAnnual Report on Form 20-F filed with SEC
04/10/12
IMMPRIMA BIOMED TO PRESENT AT CANCER IMMUNOTHERAPY CONFERENCE
03/10/12
IMMPrima to present at BIOX
21/09/12
IMMRemuneration package for incoming CEO
31/08/12
IMMAppendix 4E & 2012 Full Year Statutory Accounts
31/08/12PRICE SENSITIVE
IMMAppendix 3B
14/08/12
IMMPrima to release interim Cvac clinical data
30/07/12PRICE SENSITIVE
IMMAppendix 4C - quarterly
27/07/12PRICE SENSITIVE
IMMShareholder Briefing presentation
15/06/12
IMMShareholder Briefing - Webcast and dial in details
13/06/12
IMMPrima Newsletter
08/06/12
IMMCripto-1 program update
08/06/12PRICE SENSITIVE
IMMDubai Update
08/06/12PRICE SENSITIVE
IMMPRR to list on the Frankfurt Stock Exchange
05/06/12
IMMShareholder briefing
31/05/12
IMMInitial Director's Interest Notice
24/05/12
IMMFinal Director's Interest Notice
24/05/12
IMMChanges to the Board and senior management
24/05/12PRICE SENSITIVE
IMMDeutsche Health Care Conference
04/05/12
IMMChange of Director's Interest Notice
01/05/12
IMMAppendix 4C - quarterly
27/04/12PRICE SENSITIVE
IMMInvestor Presentation April 2012
16/04/12
IMMRegistration Statement on Form 20-F filed with SEC
13/04/12
IMMPrima BioMed to list on NASDAQ on April 16
13/04/12
IMMCanadian Patent Granted to CV
11/04/12PRICE SENSITIVE
IMMAppendix 3B
27/03/12
IMMInvestor Presentation March 2012
19/03/12
IMMAppendix 3B
15/03/12
IMMTGA Manufacturing License granted for CVac in Australia
15/03/12PRICE SENSITIVE
IMMAppendix 3B
13/03/12
IMMHalf Yearly Report and Accounts
28/02/12PRICE SENSITIVE
IMMAppendix 3B
27/02/12
IMMResponse to ASX Price Query Letter
27/02/12PRICE SENSITIVE
IMMANZGOG Cancer Vaccine Presentation
24/02/12
IMMPrima Newsletter
17/02/12
IMMFiles registration statement for listing of ADR's on NASDAQ
14/02/12
IMMPatient enrollment commences for CVac CANVAS Trial
03/02/12PRICE SENSITIVE
IMMJAPANESE PATENT GRANTED FOR CRIPTO-1 ANTIBODY
17/01/12PRICE SENSITIVE
IMMAppendix 4C - quarterly
17/01/12PRICE SENSITIVE
IMMAppendix 3B
09/01/12
IMMProgram update on Cripto-1 anti-cancer mAB
30/12/11PRICE SENSITIVE
IMMProgram update on oral cervical cancer vaccine
28/12/11PRICE SENSITIVE
IMMAppendix 3B
23/12/11
IMMAppendix 3B
16/12/11
IMMAppendix 3B
09/12/11
IMMAppendix 3B
02/12/11
IMMDeutsche Bank Presentation December 2011
02/12/11
IMMNotification of expiry of Options
25/11/11
IMMAppendix 3B
22/11/11
IMMAppendix 3B
15/11/11
IMMResults of Meeting
03/11/11
IMMChairman's Address to Shareholders
03/11/11
IMMAppendix 3B
02/11/11
IMMTeleconference details for Annual General Meeting
02/11/11
IMMPrima Newsletter
31/10/11
IMMPrima Newsletter
31/10/11
IMMCVac granted manufacturing authorisation in Germany
25/10/11PRICE SENSITIVE
IMMAppendix 3B
24/10/11
IMMPartnership with The City Hospital Dubai
24/10/11PRICE SENSITIVE
IMMAppendix 4C - quarterly
21/10/11PRICE SENSITIVE
IMMAppendix 3B
11/10/11
IMMAppendix 3B
30/09/11
IMMAnnual Report to shareholders
30/09/11
IMMNotice of Annual General Meeting/Proxy Form
30/09/11
IMMAppendix 3B
21/09/11
IMMPrima BioMed Presentation September 2011
14/09/11
IMMCVac Phase III CANVAS Ovarian Cancer Clinical Update
14/09/11PRICE SENSITIVE
IMMAppendix 3B
13/09/11
IMMPrima completes patient enrolement for CVac Phase IIb
12/09/11PRICE SENSITIVE
ACR +SandP Indices Announces September Quarterly Rebalance
09/09/11PRICE SENSITIVE
IMMAppendix 3B
05/09/11
IMMPrima BioMed included in SP-ASX 300
02/09/11
IMMAppendix 3B
31/08/11
IMMDiversity Policy
31/08/11
IMMPreliminary Final Report
31/08/11PRICE SENSITIVE
IMMAmended Appendix 3B
22/08/11
IMMAppendix 3B
22/08/11
IMMChange of Director's Interest Notice
08/08/11
IMMChange of Director's Interest Notice
08/08/11
IMMChange of Director's Interest Notice
08/08/11
IMMChange of Director's Interest Notice
08/08/11
IMMChange of Director's Interest Notice
08/08/11
IMMAppendix 3B
08/08/11
IMMEURO 4.1 MILLION GRANT TO SUPPORT CVAC
05/08/11PRICE SENSITIVE
IMMResponse to ASX Price Query
05/08/11PRICE SENSITIVE
IMMAppendix 4C - quarterly
29/07/11PRICE SENSITIVE
IMMAppendix 3B
28/07/11
PGL +Progen Subsidiary Secures New Manufacturing Contracts
20/07/11PRICE SENSITIVE
IMMAppendix 3B
19/07/11
IMMChange of Director's Interest Notice
19/07/11
IMMChange of Director's Interest Notice
19/07/11
IMMAppendix 3B
15/07/11
IMMAppendix 3B
14/07/11
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
28.5¢ 		Change
-0.020(6.56%) 		Mkt cap ! $486.6M
Open High Low Value Volume
30.5¢ 30.5¢ 28.5¢ $913.3K 3.099M

Buyers (Bids)

No. Vol. Price($)
6 124895 28.5¢
 

Sellers (Offers)

Price($) Vol. No.
29.0¢ 30287 2
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
28.5¢ 		  Change
-0.020 ( 6.80 %)
Open High Low Volume
30.5¢ 30.5¢ 28.5¢ 1420446
Last updated 15.59pm 21/11/2024 ?
IMM (ASX) Chart

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.